221 related articles for article (PubMed ID: 35579819)
1. Leveraging Machine Learning to Facilitate Individual Case Causality Assessment of Adverse Drug Reactions.
Cherkas Y; Ide J; van Stekelenborg J
Drug Saf; 2022 May; 45(5):571-582. PubMed ID: 35579819
[TBL] [Abstract][Full Text] [Related]
2. MOdified NARanjo Causality Scale for ICSRs (MONARCSi): A Decision Support Tool for Safety Scientists.
Comfort S; Dorrell D; Meireis S; Fine J
Drug Saf; 2018 Nov; 41(11):1073-1085. PubMed ID: 29876835
[TBL] [Abstract][Full Text] [Related]
3. Sorting Through the Safety Data Haystack: Using Machine Learning to Identify Individual Case Safety Reports in Social-Digital Media.
Comfort S; Perera S; Hudson Z; Dorrell D; Meireis S; Nagarajan M; Ramakrishnan C; Fine J
Drug Saf; 2018 Jun; 41(6):579-590. PubMed ID: 29446035
[TBL] [Abstract][Full Text] [Related]
4. Development of a multivariate prediction model to identify individual case safety reports which require clinical review.
Gosselt HR; Bazelmans EA; Lieber T; van Hunsel FPAM; Härmark L
Pharmacoepidemiol Drug Saf; 2022 Dec; 31(12):1300-1307. PubMed ID: 36251280
[TBL] [Abstract][Full Text] [Related]
5. Causality assessment of adverse drug reaction reports using an expert-defined Bayesian network.
Rodrigues PP; Ferreira-Santos D; Silva A; Polónia J; Ribeiro-Vaz I
Artif Intell Med; 2018 Sep; 91():12-22. PubMed ID: 30077492
[TBL] [Abstract][Full Text] [Related]
6. Towards Automating Adverse Event Review: A Prediction Model for Case Report Utility.
Muñoz MA; Dal Pan GJ; Wei YJ; Delcher C; Xiao H; Kortepeter CM; Winterstein AG
Drug Saf; 2020 Apr; 43(4):329-338. PubMed ID: 31912439
[TBL] [Abstract][Full Text] [Related]
7. Comparison of three methods (consensual expert judgement, algorithmic and probabilistic approaches) of causality assessment of adverse drug reactions: an assessment using reports made to a French pharmacovigilance centre.
Théophile H; Arimone Y; Miremont-Salamé G; Moore N; Fourrier-Réglat A; Haramburu F; Bégaud B
Drug Saf; 2010 Nov; 33(11):1045-54. PubMed ID: 20925441
[TBL] [Abstract][Full Text] [Related]
8. Validation of Artificial Intelligence to Support the Automatic Coding of Patient Adverse Drug Reaction Reports, Using Nationwide Pharmacovigilance Data.
Martin GL; Jouganous J; Savidan R; Bellec A; Goehrs C; Benkebil M; Miremont G; Micallef J; Salvo F; Pariente A; Létinier L;
Drug Saf; 2022 May; 45(5):535-548. PubMed ID: 35579816
[TBL] [Abstract][Full Text] [Related]
9. Dispositions and Causality Assessment in Pharmacovigilance: Proposing the Dx3 Approach for Assessing Causality with Small Data Sets.
Anjum RL; Chandler RE; Rocca E
Pharmaceut Med; 2022 Jun; 36(3):153-161. PubMed ID: 35486326
[TBL] [Abstract][Full Text] [Related]
10. Preliminary Results of a Novel Algorithmic Method Aiming to Support Initial Causality Assessment of Routine Pharmacovigilance Case Reports for Medication-Induced Liver Injury: The PV-RUCAM.
Scalfaro E; Streefkerk HJ; Merz M; Meier C; Lewis D
Drug Saf; 2017 Aug; 40(8):715-727. PubMed ID: 28508325
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the MOdified NARanjo Causality Scale (MONARCSi) for Individual Case Safety Reports vs. a Reference Standard.
Comfort SM; Donzanti B; Dorrell D; Dhar S; Eden C; Donaldson F
Drug Saf; 2022 Dec; 45(12):1529-1538. PubMed ID: 36273375
[TBL] [Abstract][Full Text] [Related]
12. IL-4/13 Blockade and sleep-related adverse drug reactions in over 37,000 Dupilumab reports from the World Health Organization Individual Case Safety reporting pharmacovigilance database (VigiBase™): a big data and machine learning analysis.
Alroobaea R; Rubaiee S; Hanbazazah AS; Jahrami H; Garbarino S; Damiani G; Wu J; Bragazzi NL
Eur Rev Med Pharmacol Sci; 2022 Jun; 26(11):4074-4081. PubMed ID: 35731078
[TBL] [Abstract][Full Text] [Related]
13. Feature engineering and machine learning for causality assessment in pharmacovigilance: Lessons learned from application to the FDA Adverse Event Reporting System.
Kreimeyer K; Dang O; Spiker J; Muñoz MA; Rosner G; Ball R; Botsis T
Comput Biol Med; 2021 Aug; 135():104517. PubMed ID: 34130003
[TBL] [Abstract][Full Text] [Related]
14. Adverse Drug Reaction Case Safety Practices in Large Biopharmaceutical Organizations from 2007 to 2017: An Industry Survey.
Stergiopoulos S; Fehrle M; Caubel P; Tan L; Jebson L
Pharmaceut Med; 2019 Dec; 33(6):499-510. PubMed ID: 31933240
[TBL] [Abstract][Full Text] [Related]
15. Individual Case Safety Report Replication: An Analysis of Case Reporting Transmission Networks.
van Stekelenborg J; Kara V; Haack R; Vogel U; Garg A; Krupp M; Gofman K; Dreyfus B; Hauben M; Bate A
Drug Saf; 2023 Jan; 46(1):39-52. PubMed ID: 36565374
[TBL] [Abstract][Full Text] [Related]
16. Leveraging Case Narratives to Enhance Patient Age Ascertainment from Adverse Event Reports.
Pham P; Cheng C; Wu E; Kim I; Zhang R; Ma Y; Kortepeter CM; Muñoz MA
Pharmaceut Med; 2021 Sep; 35(5):307-316. PubMed ID: 34476768
[TBL] [Abstract][Full Text] [Related]
17. A Comparison Study of Algorithms to Detect Drug-Adverse Event Associations: Frequentist, Bayesian, and Machine-Learning Approaches.
Pham M; Cheng F; Ramachandran K
Drug Saf; 2019 Jun; 42(6):743-750. PubMed ID: 30762164
[TBL] [Abstract][Full Text] [Related]
18. An Evaluation of Postmarketing Reports with an Outcome of Death in the US FDA Adverse Event Reporting System.
Marwitz K; Jones SC; Kortepeter CM; Dal Pan GJ; Muñoz MA
Drug Saf; 2020 May; 43(5):457-465. PubMed ID: 31981082
[TBL] [Abstract][Full Text] [Related]
19. Drug-induced liver injury in Switzerland: an analysis of drug-related hepatic disorders in the WHO pharmacovigilance database VigiBase from 2010 to 2020.
Ortland I; Mirjalili M; Kullak-Ublick GA; Peymani P
Swiss Med Wkly; 2021 May; 151():w20503. PubMed ID: 34000058
[TBL] [Abstract][Full Text] [Related]
20. Toward Kidney-Specific Causality Assessment Tool.
Kaya M; Duru M; Gulmez SE
Clin Ther; 2022 Jul; 44(7):e59-e75. PubMed ID: 35725506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]